Early Phase I Study of a <sup>99m</sup>Tc-Labeled Anti-Programmed Death Ligand-1 (PD-L1) Single-Domain Antibody in SPECT/CT Assessment of PD-L1 Expression in Non-Small Cell Lung Cancer.

J Nucl Med · 2019 · PMC6735283 · PMID 30796165

Europe PMC DOI

hedged sentence

0.1200

closest p · 2.4× alpha

0.1200

boldest claim

The sentences

did not reach statistical significanceP = 0.12not close (p > 0.1)

Thoracic lymph node metastases T:BP ratios were also greater at 2 h, although this difference did not reach statistical significance (mean, 2.02 vs. 1.83; P = 0.12).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.

Early Phase I Study of a &lt;sup&gt;99m&lt;/sup&gt;Tc-Labeled Anti-Programmed Death Ligand-1 (PD-L1) Single-Domain Antibody in SPECT/CT Assessment of PD-L1 Expression in Non-Small Cell Lung Cancer.

The sentences

Early Phase I Study of a <sup>99m</sup>Tc-Labeled Anti-Programmed Death Ligand-1 (PD-L1) Single-Domain Antibody in SPECT/CT Assessment of PD-L1 Expression in Non-Small Cell Lung Cancer.